Clinical trial NCT03656133: Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
Official title: Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oropharyngeal Cancer
Keywords: HPV
Radiotherapy Fractionation
Proliferation Saturation Index
Larynx
Pharynx
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
First posted: 2018-09-04
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to determine whether a mathematical model can be used to choose a radiation delivery method to improve the rate of a rapid response.

Detailed description: Investigators hypothesize that using individual patient proliferation saturation index (PSI) to select radiotherapy fractionation (conventional fractionation or hyperfractionation) may improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).

Eligibility criteria: Inclusion Criteria:

* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged ≥ 18 years
* Pathologically (histologically or cytologically) proven diagnosis of p16+ or HPV+ squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx; cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, and may consist of pathology, palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage).
* American Joint Committee on Cancer (AJCC) 8th edition staging T1-3 N0-1 MO
* Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations.
* CT or MRI performed at least 1 week apart. This can consist of diagnostic imaging and radiation therapy planning imaging.
* No evidence of distant metastases
* Eastern Cooperative Oncology Group Performance Status 0 to 3

Exclusion Criteria:

* Age \< 18
* Positive urine pregnancy test
* Evidence of distant metastases
* Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that remove all clinically and radiographically evident disease
* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* Patients with a medical condition or social situation that at the discretion of the PI would preclude them from completion of the trial

Primary outcomes:
measure: Percentage of Response at Week 4 of Treatment
timeFrame: At 4 weeks of treatment
Secondary outcomes:
measure: Rate of Complete Response at 2-3 Months
timeFrame: 2-3 months post treatment
Other outcomes:
Locations:
city: Tampa
country: United States
facility: H Lee Moffitt Cancer Center and Research Institute
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Jimmy Caudell, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: